Literature DB >> 31461765

Association between Biomarkers of Low-grade Inflammation and Sex Hormones in Women with Polycystic Ovary Syndrome.

Erifili Hatziagelaki1, Vasilios Pergialiotis2, Julia M Kannenberg3,4, Eftihios Trakakis2, Anastasia Tsiavou1, Daniel F Markgraf3,4, Maren Carstensen-Kirberg3,4, Giovanni Pacini5, Michael Roden3,4,6, George Dimitriadis1, Christian Herder3,4,6.   

Abstract

OBJECTIVE: Women with polycystic ovary syndrome (PCOS) have higher circulating levels of C-reactive protein, but the relationship between inflammation and endocrine function in PCOS remains poorly understood. Thus, this study aimed to investigate the association between low-grade inflammation and sex hormones in women with PCOS. DESIGN AND PATIENTS: A comprehensive panel of biomarkers of inflammation was measured in serum of 63 women with PCOS using proximity extension assay technology. Associations of 65 biomarkers with sex hormones were assessed without and with adjustment for age and body mass index (BMI).
RESULTS: In the unadjusted analysis, 20 biomarkers were positively correlated with 17-OH-progesterone (17-OH-P), 14 with prolactin and 6 with free testosterone, whereas inverse associations were found for 16 biomarkers with sex hormone-binding globulin (SHBG), 6 with luteinizing hormone (LH) and 6 with estrogen (all p<0.05). Among the positive associations, correlations were mainly found for five chemokines (CXCL11, CCL4, MCP-4/CCL13, CXCL5, CXCL6) and for VEGF-A, LAP-TGFβ1, TNFSF14 and MMP-1. Inverse associations with sex hormones were mainly present for two chemokines (CXCL1, MCP-2/CCL8), CDCP1, CST5 and CSF-1. Adjustment for age and BMI reduced the number of biomarker associations for SHBG and estrogen, but had hardly any impact on associations with 17-OH-P, prolactin, free testosterone and LH.
CONCLUSION: Women with PCOS feature BMI-independent associations between biomarkers of inflammation and certain sex steroid and hypophyseal hormones. Most of these inflammation-related biomarkers were chemokines, which may be relevant as potential mediators of the increased cardiometabolic risk of women with PCOS. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2019        PMID: 31461765     DOI: 10.1055/a-0992-9114

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

2.  Higher testosterone is associated with increased inflammatory markers in women with SARS-CoV-2 pneumonia: preliminary results from an observational study.

Authors:  V Di Stasi; G Rastrelli; F Inglese; M Beccaria; M Garuti; D Di Costanzo; F Spreafico; G Cervi; G F Greco; A Pecoriello; T Todisco; S Cipriani; E Maseroli; I Scavello; C Glingani; M Franchini; M Maggi; G De Donno; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2021-11-03       Impact factor: 4.256

3.  Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis.

Authors:  Juan Zou; Yukun Li; Nianchun Liao; Jue Liu; Qunfeng Zhang; Min Luo; Jiao Xiao; Yanhua Chen; Mengjie Wang; Kexin Chen; Juan Zeng; Zhongcheng Mo
Journal:  J Ovarian Res       Date:  2022-02-28       Impact factor: 4.234

4.  Might female patients benefit more from bariatric surgery with respect to inflammation.

Authors:  Qing Zhou; Pingping Yan; Haiming Shi; Ping Yan
Journal:  Front Surg       Date:  2022-08-08

5.  The Aryl hydrocarbon receptor mediates reproductive toxicity of polychlorinated biphenyl congener 126 in rats.

Authors:  Violet Klenov; Susanne Flor; Shanthi Ganesan; Malavika Adur; Nazmin Eti; Khursheed Iqbal; Michael J Soares; Gabriele Ludewig; Jason W Ross; Larry W Robertson; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2021-07-10       Impact factor: 4.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.